Precigen (PGEN) 10-Q 8 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Oct. 31, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	PRECIGEN, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PGEN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		206,738,499
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 41,728	$ 51,792
Short-term investments	72,684	48,325
Receivables
Trade, less allowance for credit losses of $5,562 and $4,825 as of September 30, 2021 and December 31, 2020, respectively	20,169	16,487
Related parties, less allowance for credit losses of $1,509 as of September 30, 2021 and December 31, 2020	66	19
Notes	0	3,689
Other	848	232
Inventory	9,936	11,359
Prepaid expenses and other	7,661	7,192
Current assets held for sale or abandonment	0	9,853
Total current assets	153,092	148,948
Long-term investments	66,926	0
Property, plant and equipment, net	32,757	34,924
Intangible assets, net	56,914	65,396
Goodwill	54,206	54,363
Right-of-use assets	11,765	9,353
Other assets	1,239	1,603
Total assets	376,899	314,587
Current liabilities
Accounts payable	3,624	4,598
Accrued compensation and benefits	8,077	8,097
Other accrued liabilities	11,258	9,549
Deferred revenue	3,693	2,800
Current portion of long-term debt	355	360
Current portion of lease liabilities	1,959	2,657
Related party payables	23	19
Current liabilities held for sale or abandonment	0	14,047
Total current liabilities	28,989	42,127
Long-term debt, net of current portion	179,817	171,522
Deferred revenue, net of current portion, including $21,205 from related parties as of September 30, 2021 and December 31, 2020	23,023	23,023
Lease liabilities, net of current portion	11,199	7,744
Deferred tax liabilities	2,574	2,897
Other long-term liabilities	50	100
Total liabilities	245,652	247,413
Commitments and contingencies (Note 16)
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 206,738,499 shares and 187,663,207 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	0	0
Additional paid-in capital	2,020,254	1,886,567
Accumulated deficit	(1,890,522)	(1,823,390)
Accumulated other comprehensive income	1,515	3,997
Total shareholders' equity	131,247	67,174
Total liabilities and shareholders' equity	$ 376,899	$ 314,587

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Accounts receivable allowance for credit losses	$ 5,562	$ 4,825
Related party receivable, allowance for credit losses	1,509	1,509
Current liabilities
Deferred revenue, net of current portion, related party	$ 23,023	$ 23,023
Shareholders' equity
Common stock, no par value (in usd per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	206,738,499	187,663,207
Common stock, shares outstanding (in shares)	206,738,499	187,663,207
Related Parties, Aggregated
Current liabilities
Deferred revenue, net of current portion, related party	$ 21,205	$ 21,205

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Total revenues	$ 21,561	$ 23,583	$ 79,652	$ 83,845
Operating Expenses
Impairment of other noncurrent assets			543	13,326
Other Expense, Net
Equity in net loss of affiliates			(3)	(1,163)
Loss from continuing operations before income taxes	(29,885)	(27,586)	(71,904)	(64,221)
Income (loss) from discontinued operations, net of income taxes	60	(1,972)	4,599	(64,769)
Net loss	$ (29,764)	$ (29,508)	$ (67,132)	$ (128,860)
Net Loss per Share
Net loss from continuing operations per share, basic (in dollars per share)	$ (0.15)	$ (0.17)	$ (0.36)	$ (0.39)
Net loss from continuing operating per share, diluted (in dollars per share)	(0.15)	(0.17)	(0.36)	(0.39)
Net income (loss) from discontinued operations per share, diluted (in dollars per share)	0	(0.01)	0.02	(0.40)
Net income (loss) from discontinued operations per share, basic (in dollars per share)	0	(0.01)	0.02	(0.40)
Net loss per share, basic (in dollars per share)	(0.15)	(0.18)	(0.34)	(0.79)
Net loss per share, diluted (in dollars per share)	$ (0.15)	$ (0.18)	$ (0.34)	$ (0.79)
Weighted average shares outstanding, basic (in shares)	199,179,963	165,527,024	197,254,438	163,318,375
Weighted average shares outstanding, diluted (in shares)	199,179,963	165,527,024	197,254,438	163,318,375
Collaboration and licensing agreements
Revenues
Total revenues	$ 22	$ 5,223	$ 389	$ 20,259
Continuing Operations
Revenues
Total revenues	21,561	23,583	79,652	83,845
Operating Expenses
Research and development	12,920	10,172	37,122	30,973
Selling, general and administrative	18,660	22,310	57,359	61,665
Impairment of other noncurrent assets	0	920	543	920
Total operating expenses	47,030	46,589	138,483	135,281
Operating loss	(25,469)	(23,006)	(58,831)	(51,436)
Other Expense, Net
Interest expense	(4,799)	(4,646)	(14,005)	(13,830)
Interest income	503	579	1,305	2,025
Other income (expense), net	(120)	10	(370)	145
Total other expense, net	(4,416)	(4,057)	(13,070)	(11,660)
Equity in net loss of affiliates	0	(523)	(3)	(1,125)
Loss from continuing operations before income taxes	(29,885)	(27,586)	(71,904)	(64,221)
Income tax benefit	61	50	173	130
Loss from continuing operations	(29,824)	(27,536)	(71,731)	(64,091)
Continuing Operations | Collaboration and licensing agreements
Revenues
Total revenues	22	5,223	389	20,259
Continuing Operations | Products
Revenues
Total revenues	7,297	6,896	22,013	20,397
Operating Expenses
Cost of products and services	7,492	7,296	19,201	21,526
Continuing Operations | Services
Revenues
Total revenues	14,117	11,288	56,851	42,615
Operating Expenses
Cost of products and services	7,958	5,891	24,258	20,197
Continuing Operations | Other
Revenues
Total revenues	$ 125	$ 176	$ 399	$ 574

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Related Party Transaction [Line Items]
Total revenues	$ 21,561	$ 23,583	$ 79,652	$ 83,845
Continuing Operations
Related Party Transaction [Line Items]
Total revenues	21,561	23,583	79,652	83,845
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Total revenues	22	5,223	389	20,259
Collaboration and licensing agreements | Continuing Operations
Related Party Transaction [Line Items]
Total revenues	22	5,223	389	20,259
Collaboration and licensing agreements | Continuing Operations | Related Parties, Aggregated
Related Party Transaction [Line Items]
Total revenues	$ 0	$ 2,823	$ 0	$ 3,053

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (29,764)	$ (29,508)	$ (67,132)	$ (128,860)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	42	(186)	(43)	86
Income (loss) on foreign currency translation adjustments	(1,068)	2,198	(2,439)	1,787
Release of cumulative translation adjustments to loss from discontinued operations	0	0	0	26,957
Comprehensive loss	$ (30,790)	$ (27,496)	$ (69,614)	$ (100,030)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balances (in shares) at Dec. 31, 2019		163,274,880
Balances at Dec. 31, 2019	$ 71,711	$ 0	$ 1,752,048	$ (27,468)	$ (1,652,869)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	13,869		13,869
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)		868,857
Shares issued upon vesting of restricted stock units and for exercises of stock options	69		69
Shares issued for accrued compensation (in shares)		1,880,405
Shares issued for accrued compensation	5,100		5,100
Shares issued as payment for services (in shares)		413,911
Shares issued as payment for services	1,006		1,006
Shares issued upon conversion of long-term debt (in shares)		6,293,402
Shares issued upon conversion of long-term debt	31,827		31,827
Shares issued in private placement or in public offering, net of issuance costs (in shares)		5,972,696
Shares issued in private placement or in public offering, net of issuance costs	35,000		35,000
Net loss	(128,860)				(128,860)
Release of cumulative translation adjustments to loss from discontinued operations	26,957			26,957
Other comprehensive income (loss)	1,873			1,873
Balances (in shares) at Sep. 30, 2020		178,704,151
Balances at Sep. 30, 2020	58,552	$ 0	1,838,919	1,362	(1,781,729)
Balances (in shares) at Jun. 30, 2020		172,285,932
Balances at Jun. 30, 2020	49,542	$ 0	1,802,413	(650)	(1,752,221)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	4,600		4,600
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)		28,389
Shares issued upon vesting of restricted stock units and for exercises of stock options	3		3
Shares issued for accrued compensation (in shares)		75,000
Shares issued for accrued compensation	0
Shares issued as payment for services (in shares)		21,428
Shares issued as payment for services	76		76
Shares issued upon conversion of long-term debt (in shares)		6,293,402
Shares issued upon conversion of long-term debt	31,827		31,827
Net loss	(29,508)				(29,508)
Release of cumulative translation adjustments to loss from discontinued operations	0
Other comprehensive income (loss)	2,012			2,012
Balances (in shares) at Sep. 30, 2020		178,704,151
Balances at Sep. 30, 2020	$ 58,552	$ 0	1,838,919	1,362	(1,781,729)
Balances (in shares) at Dec. 31, 2020	187,663,207	187,663,207
Balances at Dec. 31, 2020	$ 67,174	$ 0	1,886,567	3,997	(1,823,390)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	11,462		11,462
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)		1,750,521
Shares issued upon vesting of restricted stock units and for exercises of stock options	603		603
Shares issued as payment for services (in shares)		74,771
Shares issued as payment for services	577		577
Shares issued in private placement or in public offering, net of issuance costs (in shares)		17,250,000
Shares issued in private placement or in public offering, net of issuance costs	121,045		121,045
Net loss	(67,132)				(67,132)
Release of cumulative translation adjustments to loss from discontinued operations	0
Other comprehensive income (loss)	$ (2,482)			(2,482)
Balances (in shares) at Sep. 30, 2021	206,738,499	206,738,499
Balances at Sep. 30, 2021	$ 131,247	$ 0	2,020,254	1,515	(1,890,522)
Balances (in shares) at Jun. 30, 2021		206,580,928
Balances at Jun. 30, 2021	159,196	$ 0	2,017,413	2,541	(1,860,758)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	2,490		2,490
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)		157,571
Shares issued upon vesting of restricted stock units and for exercises of stock options	351		351
Net loss	(29,764)				(29,764)
Release of cumulative translation adjustments to loss from discontinued operations	0
Other comprehensive income (loss)	$ (1,026)			(1,026)
Balances (in shares) at Sep. 30, 2021	206,738,499	206,738,499
Balances at Sep. 30, 2021	$ 131,247	$ 0	$ 2,020,254	$ 1,515	$ (1,890,522)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (67,132)	$ (128,860)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,442	13,701
Loss on disposals of assets, net	89	1,606
Impairment of goodwill	0	9,635
Impairment of other noncurrent assets	543	13,326
Gain on sale of discontinued operations	0	(672)
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	0	26,957
Unrealized depreciation on equity securities	0	106
Amortization of premiums (discounts) on investments, net	893	(652)
Equity in net loss of affiliates	3	1,163
Stock-based compensation expense	11,462	13,869
Shares issued as payment for services	577	1,006
Provision for credit losses	1,219	759
Accretion of debt discount and amortization of deferred financing costs	8,641	7,807
Deferred income taxes	(180)	(204)
Other noncash items	(4,600)	108
Receivables:
Trade	(5,285)	952
Related parties	(47)	265
Other	(610)	1,807
Inventory	1,422	5,411
Prepaid expenses and other	(388)	(1,777)
Other assets	282	(125)
Accounts payable	(678)	(1,556)
Accrued compensation and benefits	(304)	(1,605)
Other accrued liabilities	1,505	(3,072)
Deferred revenue	903	(20,304)
Lease liabilities	107	(508)
Related party payables	4	305
Other long-term liabilities	(50)	0
Net cash used in operating activities	(41,182)	(60,552)
Cash flows from investing activities
Purchases of investments	(174,221)	(171,360)
Sales and maturities of investments	82,000	96,000
Purchases of property, plant and equipment	(4,474)	(6,058)
Proceeds from sale of assets	2,537	1,831
Proceeds from sale of discontinued operations, net of cash sold	0	64,240
Proceeds from repayment of notes receivable	3,689	2,942
Net cash used in investing activities	(90,469)	(12,405)
Cash flows from financing activities
Proceeds from issuance of shares, net of issuance costs	121,045	35,000
Advances from lines of credit	0	10,005
Repayments of advances from lines of credit	0	(11,927)
Payments of long-term debt	(351)	(370)
Proceeds from stock option exercises	603	69
Net cash provided by financing activities	121,297	32,777
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	264	(77)
Net decrease in cash, cash equivalents, and restricted cash	(10,090)	(40,257)
Cash, cash equivalents, and restricted cash
Beginning of period	52,250	68,434
End of period	42,160	28,177
Supplemental disclosure of cash flow information
Cash paid during the period for interest	7,116	7,155
Cash paid during the period for income taxes	4	48
Significant noncash activities
Stock issued upon conversion of long-term debt	0	31,827
Accrued compensation paid in equity awards	0	5,100
Purchases of property and equipment included in accounts payable and other accrued liabilities	108	461
Proceeds from sale of assets included in accounts receivable	124	435
Cash, cash equivalents, and restricted cash
Cash and cash equivalents	41,728
Restricted cash included in other assets	432
Cash, cash equivalents, and restricted cash	$ 42,160	$ 28,177

Organization

Organization	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland. Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium. Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa. Trans Ova Genetics, L.C., including its wholly owned subsidiary Progentus, L.C., are providers of reproductive technologies, including services and products sold to cattle breeders and other producers and are hereinafter collectively referred to as "Trans Ova." Trans Ova is a wholly owned subsidiary with primary operations in California, Iowa, Maryland, Missouri, Texas, Washington, and Wisconsin. Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform ("MBP") assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and had substantially completed the wind down by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion. On January 31, 2020, Precigen completed the sale of the majority of its non-healthcare assets and operations to an affiliate of Third Security, LLC ("Third Security"), a related party, which are presented as discontinued operations for the nine months ended September 30, 2020. See Notes 3 and 13 for further discussion. Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company."

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and note disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2021 and results of operations and cash flows for the interim periods ended September 30, 2021 and 2020. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2021, or for any other future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying condensed consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated. Liquidity Management believes that existing liquid assets as of September 30, 2021 will allow the Company to continue its operations for at least a year from the issuance date of these condensed consolidated financial statements. These condensed consolidated financial statements are presented in United States dollars. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of therapeutic product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development, and clinical manufacturing of its and its collaborators' therapeutic product candidates. Additionally, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the nine months ended September 30, 2021, the Company incurred a net loss of $67,132 and, as of September 30, 2021, had an accumulated deficit of $1,890,522. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, adequately satisfy or renegotiate long-term debt obligations, obtain regulatory approval of its therapeutic product candidates, successfully commercialize its therapeutic product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations. Risks and Uncertainties COVID-19 has had and continues to have an extensive impact on the global health and economic environments. Commencing in the second half of March 2020, the Company's healthcare business began to experience delays to certain of its clinical trials as a result of COVID-19. For example, starting in March 2020, the Company temporarily suspended the last cohort of the Phase 1b/2a clinical trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, its employees, and contractors. The temporary suspension of the AG019 trial was voluntary and was not related to any patient safety issues in the study. The voluntary suspension of the AG019 trial was lifted in June 2020, and recruitment in the study resumed. Additionally, from April to May 2020, enrollment of new patients in the Company's PRGN-3005 Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. The temporary suspension of the PRGN-3005 trial was not related to safety issues in the studies, and in May 2020, recruitment resumed in the PRGN-3005 Phase 1 trial. Furthermore, there is uncertainty regarding the duration and severity of the ongoing pandemic, and the Company could experience further delays or other pandemic-related events that may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future. The Company is closely monitoring the impact of COVID-19 on these and other aspects of its business, including Trans Ova and Exemplar. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses. See Note 3 for further discussion of the impact of COVID-19 on MBP Titan. Equity Method Investments The Company accounts for its investments in each of its joint ventures ("JVs") and accounted for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. See additional discussion related to certain of the Company's JVs in Note 4 and additional discussion related to certain of the Harvest start-up entities in Note 16. Variable Interest Entities As of September 30, 2021 and December 31, 2020, the Company determined that its JVs were variable interest entities ("VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. As of September 30, 2021 and December 31, 2020, the Company had no risk of loss related to the identified VIEs. See Note 4 for discussion of the Company's future funding commitments for its significant JVs. Segment Information The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. Starting in the first quarter of 2021, the financial information regularly reviewed by the CODM was revised and the operating segments, which were determined to be operating and reportable segments, were (i) Biopharmaceuticals, (ii) Exemplar, and (iii) Trans Ova. The legal entities of PGEN Therapeutics and ActoBio, as well as the Company's majority-owned subsidiary Triple-Gene LLC and its partnered program with Castle Creek Biosciences, Inc. (" Castle Creek"), represent the Biopharmaceuticals reportable segment as these businesses share resources and the CODM manages these operations as a group. See Note 1 for a description of PGEN Therapeutics, ActoBio, Exemplar, and Trans Ova. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, gain or loss on disposals of assets, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates. As a result of the revision of the reportable segments, the Company has restated its historical segment presentation to conform to the revised segment determination. See Note 19 for further discussion of the Company's segments. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification ("ASC") Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. The Company adopted this standard effective January 1, 2021, and there was no material impact to the accompanying condensed consolidated financial statements. Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06" ) . The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021, and is effective for the Company for the year ending December 31, 2022. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations Where applicable, the notes to the accompanying condensed consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations based on the discontinued operations summarized below. MBP Titan As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially completed by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. This discontinuation of operations represented the continuation of a strategic shift to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges that the Company commenced as part of the Transactions defined and discussed below. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are reclassified and presented as discontinued operations in the accompanying condensed consolidated financial statements for all periods. The January 2021 sale of property and equipment resulted in a gain on disposal of assets of $464, which is included in income from discontinued operations in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2021. In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility that were originally due to expire in July 2025. This lease termination resulted in a gain of $4,602, which is included in income from discontinued operations in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2021. After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), and Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), including the associated deferred revenue remaining under each collaboration agreement (Notes 4 and 5), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying condensed consolidated financial statements for all periods presented as a result of the Company's continuing involvement. The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale or abandonment related to MBP Titan as of September 30, 2021 and December 31, 2020, are as follows: September 30, December 31, Assets Property, plant and equipment, net $ — $ 586 Right-of-use assets — 9,131 Other assets — 136 Total assets held for sale or abandonment $ — $ 9,853 Liabilities Lease liabilities, current $ — $ 1,890 Other current liabilities — 619 Lease liabilities, net of current portion — 11,538 Total liabilities held for sale or abandonment $ — $ 14,047 The following table presents the financial results of discontinued operations related to MBP Titan: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating (gains) expenses (1) $ (60) $ 1,972 $ (4,599) $ 38,713 Operating income (loss) 60 (1,972) 4,599 (38,713) Income (loss) before income taxes 60 (1,972) 4,599 (38,713) Income (loss) from discontinued operations $ 60 $ (1,972) $ 4,599 $ (38,713) (1) Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and right-of-use assets of $12,406 in the nine months ended September 30, 2020 in conjunction with the suspension of MBP Titan's operations discussed above. The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan that are included in the accompanying condensed consolidated statements of cash flows. Nine Months Ended 2021 2020 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 2,337 Impairment of goodwill — 9,635 Impairment of other noncurrent assets — 12,406 (Gain) loss on disposals of assets, net (464) 13 Stock-based compensation expense — (34) Gain on lease termination (1) (4,602) — Cash flows from investing activities Purchases of property, plant and equipment — (88) Proceeds from sales of assets 1,083 — (1) Included in other noncash items on the accompanying condensed consolidated statement of cash flows. Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc. On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's non-healthcare assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities that were directly related to the subsidiaries sold: • Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc.; • Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which focused on biological insect solutions; • ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds; and • Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations that were previously an operating division within Precigen. Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions". The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represented a strategic shift of the Company towards the Company becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The operations related to the Transactions are reclassified and presented as discontinued operations in the accompanying condensed consolidated financial statements for all periods. Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $26,957 were released to earnings and included in loss from discontinued operations. See further discussion below. The following table presents the financial results of discontinued operations related to the Transactions for the nine months ended September 30, 2020. There were no discontinued operations related to the Transactions for the three months ended September 30, 2020. Nine Months Ended September 30, 2020 TS Biotechnology Sale EnviroFlight Sale Total Revenues (1) $ 1,294 $ — $ 1,294 Operating expenses 896 — 896 Operating income 398 — 398 Gain on sale of discontinued operations 633 39 672 Loss on release of cumulative foreign currency translation adjustment (26,957) — (26,957) Other expense, net (129) — (129) Equity in net loss of affiliates — (38) (38) Income (loss) before income taxes (26,055) 1 (26,054) Income tax expense (2) — (2) Income (loss) from discontinued operations $ (26,057) $ 1 $ (26,056) (1) Includes revenue recognized from related parties of $436. The following table presents the significant noncash items and purchases of property, plant and equipment for the discontinued operations related to the Transactions that are included in the accompanying condensed consolidated statement of cash flows. Nine Months Ended Adjustments to reconcile net loss to net cash used in operating activities Gain on sale of discontinued operations $ (672) Loss on release of cumulative foreign currency translation adjustment 26,957 Unrealized depreciation on equity securities 106 Equity in net loss of EnviroFlight 38 Stock-based compensation expense (1,346) Cash flows from investing activities Purchases of property, plant and equipment (382) Also see Note 13 regarding TS Biotechnology's purchase of the Company's common stock in January 2020, concurrent with the TS Biotechnology Sale. Equity Method Investments The Company accounted for its investment in EnviroFlight using the equity method of accounting. Summarized financial data for EnviroFlight is shown in the following table for the period in which the Company held the equity method investment. Nine Months Ended Revenues $ 16 Operating expenses 92 Operating loss (76) Net loss $ (76) Out-of-Period Adjustment During the nine months ended September 30, 2020, the Company recorded an out-of-period adjustment of $26,572 to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Sale. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Sale nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's results of operations for the nine months ended September 30, 2020.

Investments in Joint Ventures

Investments in Joint Ventures	9 Months Ended
	Sep. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, a JV formed to optimize and scale-up the Company's MBP technology for the production of certain fuels and lubricants. The Company also entered into an exclusive channel collaboration ("ECC") with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of September 30, 2021, the Company's remaining commitment was $4,225. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(428) and $(425) as of September 30, 2021 and December 31, 2020, respectively, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners. See Note 3 for additional discussion regarding the Company's investment in Intrexon Energy Partners. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, a JV formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of September 30, 2021, the Company's remaining commitment was $10,000. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(435) as of September 30, 2021 and December 31, 2020, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II. See Notes 3 and 16 for additional discussion regarding the Company's investment in Intrexon Energy Partners II.

Collaboration and Licensing Rev

Collaboration and Licensing Revenue	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Revenue	Collaboration and Licensing Revenue Historically, the Company has derived collaboration and licensing revenue through agreements with counterparties for the development and commercialization of products enabled by the Company's technology platforms. These collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. The Company recognizes the reimbursement payments received for research and development efforts in the period when the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services, and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if any milestones will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC Topic 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2021 and 2020. Three Months Ended Nine Months Ended 2021 2020 2021 2020 ZIOPHARM Oncology, Inc. $ — $ — $ — $ 100 Oragenics, Inc. — 2,823 — 3,053 Castle Creek Biosciences, Inc. 18 2,394 371 16,967 Other 4 6 18 139 Total (1) $ 22 $ 5,223 $ 389 $ 20,259 (1) Collaboration and licensing revenues include the recognition of $22 and $5,213 for the three months ended September 30, 2021 and 2020, respectively, and $380 and $19,654 for the nine months ended September 30, 2021 and 2020, respectively, associated with upfront and milestone payments which were previously deferred. There have been no significant changes to the agreements with our collaborators and licensees in the nine months ended September 30, 2021. Deferred Revenue Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consisted of the following: September 30, December 31, Collaboration and licensing agreements $ 23,040 $ 23,420 Prepaid product and service revenues 3,493 2,126 Other 183 277 Total $ 26,716 $ 25,823 Current portion of deferred revenue $ 3,693 $ 2,800 Long-term portion of deferred revenue 23,023 23,023 Total $ 26,716 $ 25,823 Revenue is recognized under collaboration and licensing agreements as services are performed. Certain of the arrangements are not active while the other party evaluates the status of the project and its desired future development activities. The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2021 and December 31, 2020, as well as the estimated remaining performance period as of September 30, 2021. Average Remaining Performance Period (Years) September 30, December 31, Intrexon Energy Partners, LLC 2.5 $ 8,362 $ 8,362 Intrexon Energy Partners II, LLC 3.2 12,843 12,843 Castle Creek Biosciences, Inc. 0.3 17 379 Other 3.1 1,818 1,836 Total $ 23,040 $ 23,420

Short-term and Long-term Invest

Short-term and Long-term Investments	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Short-term and Long-term Investments	Short-term and Long-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of September 30, 2021: Amortized Gross Gross Aggregate U.S. government debt securities $ 139,375 $ 5 $ (35) $ 139,345 Certificates of deposit 265 — — 265 Total $ 139,640 $ 5 $ (35) $ 139,610 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2020: Amortized Gross Gross Aggregate U.S. government debt securities $ 48,048 $ 14 $ (1) $ 48,061 Certificates of deposit 264 — — 264 Total $ 48,312 $ 14 $ (1) $ 48,325 The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2021 was: Due within one year $ 72,684 After one year through two years 66,926 Total $ 139,610 Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's debt security investments are not significant as of September 30, 2021.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of September 30, 2021: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs September 30, Assets U.S. government debt securities $ — $ 139,345 $ — $ 139,345 Certificates of deposit — 265 — 265 Total $ — $ 139,610 $ — $ 139,610 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2020: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 48,061 $ — $ 48,061 Certificates of deposit — 264 — 264 Total $ — $ 48,325 $ — $ 48,325 The method used to estimate the fair value of the Level 2 short-term and long-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Liabilities The carrying values of the Company's long-term debt, excluding the 3.50% convertible senior notes due 2023 (the "Convertible Notes"), approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The calculated fair value of the Convertible Notes (Note 11) was approximately $169,000 and $165,000 as of September 30, 2021 and December 31, 2020, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying condensed consolidated balance sheets at amortized cost, which was $176,788 and $168,147 as of September 30, 2021 and December 31, 2020, respectively.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: September 30, December 31, Supplies, embryos and other production materials $ 2,230 $ 2,060 Work in process 1,837 2,348 Livestock 3,803 5,047 Feed 2,066 1,904 Total inventory $ 9,936 $ 11,359

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment consist of the following: September 30, December 31, Land and land improvements $ 9,844 $ 9,844 Buildings and building improvements 12,088 12,088 Furniture and fixtures 1,236 1,228 Equipment 32,634 31,150 Leasehold improvements 6,452 6,260 Breeding stock 968 868 Computer hardware and software 5,425 5,684 Construction and other assets in progress 2,729 2,754 71,376 69,876 Less: Accumulated depreciation and amortization (38,619) (34,952) Property, plant and equipment, net $ 32,757 $ 34,924 Depreciation expense was $1,525 and $1,873 for the three months ended September 30, 2021 and 2020, respectively, and $4,711 and $5,689 for the nine months ended September 30, 2021 and 2020, respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the nine months ended September 30, 2021 were as follows: Balance at December 31, 2020 $ 54,363 Foreign currency translation adjustments (157) Balance at September 30, 2021 $ 54,206 The Company had $43,643 of cumulative impairment losses as of September 30, 2021 and December 31, 2020. Intangible assets consist of the following as of September 30, 2021: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 92,859 $ (37,667) $ 55,192 Customer relationships 10,850 (10,024) 826 Trademarks 5,900 (5,004) 896 Total $ 109,609 $ (52,695) $ 56,914 Intangible assets consist of the following as of December 31, 2020: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 96,927 $ (34,412) $ 62,515 Customer relationships 10,850 (9,340) 1,510 Trademarks 5,900 (4,529) 1,371 Total $ 113,677 $ (48,281) $ 65,396

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Lines of Credit and Long-Term Debt	Lines of Credit and Long-Term Debt Lines of Credit Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha that matures on April 1, 2022. The line of credit bears interest at the greater of the U.S. Prime Rate or 3.00%, and the actual rate was 3.25% as of September 30, 2021. As of September 30, 2021 and December 31, 2020, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $5,000 as of September 30, 2021. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2022. As of September 30, 2021, the line of credit bore interest at 4.00% per annum. As of September 30, 2021 and December 31, 2020, there was no outstanding balance. Long-Term Debt Long-term debt consists of the following: September 30, December 31, Convertible debt $ 176,788 $ 168,147 Notes payable 3,328 3,655 Other 56 80 Long-term debt 180,172 171,882 Less current portion 355 360 Long-term debt, less current portion $ 179,817 $ 171,522 Convertible Debt Precigen Convertible Notes In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042. The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the three months ended September 30, 2021. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date. If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount. As of September 30, 2021, the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $176,788. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02%. As of September 30, 2021, the unamortized long-term debt discount and debt issuance costs totaled $23,212. The components of interest expense related to the Convertible Notes were as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cash interest expense $ 1,750 $ 1,750 $ 5,250 $ 5,250 Non-cash interest expense 3,011 2,706 8,641 7,807 Total interest expense $ 4,761 $ 4,456 $ 13,891 $ 13,057 Accrued interest of $1,750 is included in other accrued liabilities on the accompanying condensed consolidated balance sheet as of September 30, 2021. ActoBio Convertible Notes In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest. The ActoBio Notes, which accrued interest at 3.0% compounded annually ("accrued PIK interest"), matured in September 2020. The Company issued 6,293,402 shares of Precigen common stock upon conversion of the outstanding principal balance and accrued PIK interest at maturity. Interest expense was $147 and $616 for the three and nine months ended September 30, 2020, respectively. Precigen and PGEN Therapeutics Convertible Note In December 2018, in conjunction with the Securities Purchase, Assignment and Assumption Agreement with Ares Trading S.A. ("Ares Trading"), Precigen and PGEN Therapeutics jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. In October 2020, pursuant to the terms of the Merck Note, Ares Trading voluntarily elected to convert the entire $25,000 outstanding into 6,758,400 shares of Precigen common stock. Notes Payable Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $3,328 as of September 30, 2021. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets. Future Maturities Future maturities of long-term debt as of September 30, 2021 are as follows: 2021 $ 90 2022 400 2023 200,363 2024 378 2025 393 2026 408 Thereafter 1,352 Total $ 203,384

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. The Company has U.S. taxable loss of approximately $24,700 and $26,900 for the three months ended September 30, 2021 and 2020, respectively, and $82,200 and $133,900 for the nine months ended September 30, 2021 and 2020, respectively. The following table presents the components of income tax benefit from continuing operations. Three Months Ended Nine Months Ended 2021 2020 2021 2020 Current foreign income tax expense from continuing operations $ — $ 18 $ 7 $ 74 Deferred income tax benefit from continuing operations (61) (68) (180) (204) Total income tax benefit from continuing operations $ (61) $ (50) $ (173) $ (130) The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $2,574, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. As of September 30, 2021, the Company has net operating loss carryforwards for U.S. federal income tax purposes of approximately $836,600 available to offset future taxable income, including approximately $583,900 generated after 2017, U.S. capital loss carryforwards of approximately $212,500, and federal and state research and development tax credits of approximately $10,900, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. Net operating loss carryforwards generated prior to 2018 will begin to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. As of September 30, 2021, the Company's foreign subsidiaries have foreign loss carryforwards of approximately $76,800, most of which do not expire.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Issuances of Precigen Common Stock In January 2021, the Company closed a public offering of 17,250,000 shares of its common stock, resulting in net proceeds of $121,045 after deducting underwriting discounts and $568 of capitalized offering expenses. Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020. See Notes 11 and 16 for discussion regarding additional issuances of Precigen common stock. Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 11), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within five The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement. Components of Accumulated Other Comprehensive Income The components of accumulated other comprehensive income are as follows: September 30, December 31, Unrealized gain (loss) on investments $ (30) $ 13 Income on foreign currency translation adjustments 1,545 3,984 Total accumulated other comprehensive income $ 1,515 $ 3,997

Share-Based Payments

Share-Based Payments	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Payments	Share-Based Payments The Company measures the fair value of stock options and restricted stock units ("RSUs") issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the condensed consolidated statements of operations are presented below: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of products $ 8 $ 1 $ 23 $ 7 Cost of services 35 35 134 99 Research and development 555 435 2,180 1,383 Selling, general and administrative 1,892 4,157 9,125 13,760 Discontinued operations — (28) — (1,380) Total $ 2,490 $ 4,600 $ 11,462 $ 13,869 Precigen Stock Option Plans In April 2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share-based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of September 30, 2021, there were 104,354 stock options outstanding under the 2008 Plan. Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of September 30, 2021, there were 27,000,000 shares authorized for issuance under the 2013 Plan, of which 11,078,437 stock options and 306,360 RSUs were outstanding and 5,900,357 shares were available for grant. In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of September 30, 2021, there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 1,066,318 stock options and 162,121 RSUs were outstanding and 1,974,662 shares were available for grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2020 11,255,896 $ 15.53 7.25 Granted 1,802,820 8.02 Exercised (126,508) (4.77) Forfeited (255,467) (6.83) Expired (427,632) (25.93) Balances at September 30, 2021 12,249,109 14.35 6.89 Exercisable at September 30, 2021 7,227,624 16.87 5.68 RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2020 1,727,712 $ 6.11 0.42 Granted 462,019 7.87 Vested (1,624,013) (5.76) Forfeited (97,237) (8.96) Balances at September 30, 2021 468,481 8.47 0.58 Precigen currently uses authorized and unissued shares to satisfy share award exercises. The Company's Executive Chairman ("Executive Chairman"), who previously served as an employee and executive officer until September 24, 2020, received a base salary of $200 per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale. In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman consisting of (i) an annual retainer of $100 payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully vested stock options having a grant date fair value of $250; and (iii) an annual grant of RSUs having a grant date fair value of $250 vesting over one year. The new compensation arrangement began in calendar year 2021 and was prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. Expense associated with the arrangements above is included in selling, general, and administrative expenses in the Company's condensed consolidated statements of operations and totaled $76 and $266 for the three months ended September 30, 2021 and 2020, respectively, and $585 and $720 for the nine months ended September 30, 2021 and 2020, respectively.

Operating Leases

Operating Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Operating Leases	Operating LeasesThe Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of one The components of lease costs were as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating lease costs $ 843 $ 892 $ 2,511 $ 2,690 Short-term lease costs 464 480 1,411 1,332 Variable lease costs 199 205 663 654 Lease costs $ 1,506 $ 1,577 $ 4,585 $ 4,676 As of September 30, 2021, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2021 $ 718 2022 3,405 2023 2,945 2024 3,009 2025 2,283 2026 1,796 Thereafter 4,638 Total 18,794 Present value adjustment (5,636) Total $ 13,158 Current portion of operating lease liabilities $ 1,959 Long-term portion of operating lease liabilities 11,199 Total $ 13,158 Other information related to operating leases in continuing operations was as follows: September 30, December 31, Weighted average remaining lease term (years) 6.38 4.21 Weighted average discount rate 10.99 % 10.27 % Nine Months Ended 2021 2020 Supplemental disclosure of cash flow information Cash paid for operating lease liabilities $ 2,835 $ 3,013 Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases) 4,868 395

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies On December 1, 2020, Trans Ova settled one of two patent infringement lawsuits brought by XY, LLC ("XY"). The lawsuit, originally filed in 2012, was tried and appealed between 2016 and 2020. On December 1, 2020, the parties reached a settlement resolving all remaining disputes. As part of that settlement, Trans Ova remitted to XY a settlement payment, which, in addition to all the other monies Trans Ova had previously paid XY, constituted full payment and satisfaction of the judgment, including pre-judgment interest, post-judgment interest, costs, and all past, current and future royalty obligations under the judgment. In exchange, XY released and forever discharged Trans Ova from all obligations arising out of the judgment. A second patent infringement lawsuit brought on by XY was filed in December 2016. There are currently five patents remaining at issue in the case. The Company expects the trial to occur sometime in early 2023. While this patent infringement lawsuit is pending, Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of district court and appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. In September 2020, the Company reached a final settlement with the Securities and Exchange Commission ("SEC") with respect to an investigation concerning the Company's disclosures regarding its MBP program in the first three quarters of 2017. Under the terms of the settlement, the Company, without admitting or denying the allegations of the SEC, consented to the entry of an administrative order requiring that the Company: (i) cease and desist from committing or causing any violations and future violations under Section 13(a) of the Securities Exchange Act of 1934, as amended, and Rules 13a-11 and 12b-20 promulgated thereunder; and (ii) pay a $2,500 civil money penalty to the SEC. In October 2020, several purported shareholder class action lawsuits were filed in the U.S. District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiff's claims track the allegations in the SEC's administrative order described above but challenge disclosures about the MBP program through September 2020, i.e., the date of the SEC administrative order. The plaintiffs seek compensatory damages, interest, and an award of reasonable attorney's fees and costs. In April 2021, the court granted an order consolidating the claims and appointed a lead plaintiff and lead counsel in the case, captioned Abailla v. Precigen, Inc., F/K/A Intrexon Corp., et al . In May 2021, the lead plaintiff filed an amended complaint. The defendants moved to dismiss that complaint. In September 2021, the court issued an order mooting the defendants' motion to dismiss in light of the lead plaintiff's stated intent to file a second amended complaint in response to the motion to dismiss. On September 27, 2021, the lead plaintiff filed a second amended complaint. The defendants intend to move to dismiss that complaint. In December 2020, a derivative shareholder action, captioned Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al , was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. asserting similar claims under state law against Precigen's current directors and certain officers. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The case was stayed by an order entered on June 14, 2021. On September 24, 2021, an individual shareholder filed a lawsuit in the Circuit Court for Henrico County styled Kent v. Precigen, Inc. , Case CL21-6349. The Kent action demands inspection of certain books and records of the Company pursuant to Virginia statutory and common law. The Company intends to defend the lawsuits vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits. On July 10, 2020, the Company received a notice of arbitration from Harvest pursuant to the Collaboration Investment Opportunity Agreement dated March 13, 2015. In December 2020, the Company entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and to settle all claims made in connection with the notice of arbitration noted above. Pursuant to the settlement agreement, the Company issued 2,117,264 shares of its common stock to Harvest valued at $18,103 in consideration of (i) the termination of the ECC agreements with Thrive Agrobiotics, Inc., Exotech Bio, Inc., and AD Skincare, Inc., which the Company had $6,993 of deferred revenue remaining related to these ECCs prior to the settlement agreement; (ii) the return of the Company's ownership interest in these Harvest start-up entities that had a total value of $326 prior to the settlement agreement; (iii) the commitment of Harvest (which is still ongoing) to take reasonable commercial efforts to transfer to the Company its membership interests in Intrexon Energy Partners II; and (iv) mutual irrevocable and unconditional releases of claims. The Company wrote off the investment balances and netted the deferred revenue balances associated with the eliminated service obligation against the consideration paid. Outstanding receivables from these Harvest start-up entities related to research and development services performed by the Company under the ECC agreements, which had been fully reserved in 2019, were also forgiven as part of the settlement agreement and written off by the Company. Following the settlement agreement, these Harvest start-up entities are no longer related parties. The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including the IEP Investors and the IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding as of September 30, 2021. These disagreements and disputes result in management distraction and may result in litigation, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company's business or operations. In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2021, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns 100% of the equity interests of Third Security. The Company has an agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf. The total expenses incurred by the Company under these arrangements were $43 and $56 for the three months ended September 30, 2021 and 2020, respectively, and $89 and $132 for the nine months ended September 30, 2021 and 2020, respectively. See also Note 14 regarding compensation arrangements between the Company and its Executive Chairman. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $20 and $18 for the three months ended September 30, 2021 and 2020, respectively, and $61 and $64 for the nine months ended September 30, 2021 and 2020, respectively. See Notes 1, 3, and 13 regarding additional transactions with affiliates of Third Security. Transactions with ECC Parties Collaborators in which the Company holds more than a de minimis equity interest, including interests received as upfront or milestone payments through collaborations, are considered related parties. The Company held Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), a convertible note, common shares of Castle Creek, and warrants to purchase shares of Castle Creek common stock previously acquired through collaborations and other transactions. As a result of the acquisition of Castle Creek by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek Pharmaceutical") in December 2019, the Company received $1,280 in December 2019 for its shares of Castle Creek common stock and received a total of $3,311 in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. Subsequent to the acquisition by Castle Creek Pharmaceutical, Castle Creek is no longer a related party.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The following table presents the computation of basic and diluted net income (loss) per share: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Historical net loss per share: Numerator: Net loss from continuing operations $ (29,824) $ (27,536) $ (71,731) $ (64,091) Net income (loss) from discontinued operations 60 (1,972) 4,599 (64,769) Net loss $ (29,764) $ (29,508) $ (67,132) $ (128,860) Denominator: Weighted average shares outstanding, basic and diluted 199,179,963 165,527,024 197,254,438 163,318,375 Net loss per share: Net loss from continuing operations per share, basic and diluted $ (0.15) $ (0.17) $ (0.36) $ (0.39) Net income (loss) from discontinued operations per share, basic and diluted — (0.01) 0.02 (0.40) Net loss per share, basic and diluted $ (0.15) $ (0.18) $ (0.34) $ (0.79) The following potentially dilutive securities as of September 30, 2021 and 2020, have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended as they would have been anti-dilutive: September 30, 2021 2020 Convertible debt 11,732,440 17,843,715 Options 12,249,109 11,379,605 Restricted stock units 468,481 1,813,043 Warrants 121,888 133,264 Total 24,571,918 31,169,627

Segments

Segments	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segments	Segments The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net loss of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates, but includes proceeds from the sale of assets in the period sold. During the nine months ended September 30, 2021, the Company modified the definition of Segment Adjusted EBITDA to exclude the gain or loss on disposals of assets and include proceeds from the sale of assets in the period sold. Segment Adjusted EBITDA for the three and nine months ended September 30, 2020 was restated to reflect this change. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3). For the three and nine months ended September 30, 2021, the Company's reportable segments were (i) Biopharmaceuticals, (ii) Exemplar, and (iii) Trans Ova. These identified reportable segments met the quantitative thresholds to be reported separately for the nine months ended September 30, 2021. See Note 2 for a description of Biopharmaceuticals. See Note 1 for a description of Exemplar and Trans Ova. Segment Adjusted EBITDA by reportable segment was as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Biopharmaceuticals $ (12,661) $ (8,761) $ (34,055) $ (26,106) Exemplar 1,617 1,654 5,312 2,511 Trans Ova (2,552) (251) 15,881 7,417 Segment Adjusted EBITDA for reportable segments $ (13,596) $ (7,358) $ (12,862) $ (16,178) The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Segment Adjusted EBITDA for reportable segments $ (13,596) $ (7,358) $ (12,862) $ (16,178) Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates 1,962 244 3,360 3,395 Add recognition of previously deferred revenue associated with upfront and milestone payments 1,163 7,132 1,849 25,178 Other expenses: Interest expense (4,799) (4,646) (14,005) (13,830) Depreciation and amortization (3,399) (3,786) (10,442) (11,364) Loss on disposals of assets (318) (615) (553) (1,593) Impairment losses — (920) (543) (920) Stock-based compensation expense (2,490) (4,628) (11,462) (15,249) Adjustment related to accrued bonuses paid in equity awards — — — 2,833 Equity in net loss of affiliates — (523) (3) (1,125) Other (5) 4 (19) 16 Unallocated corporate costs (7,166) (10,452) (25,412) (29,102) Eliminations (1,237) (2,038) (1,812) (6,282) Consolidated net loss from continuing operations before income taxes $ (29,885) $ (27,586) $ (71,904) $ (64,221) Revenues by reportable segment were as follows: Three Months Ended September 30, 2021 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 129 $ 3,204 $ 18,228 $ 21,561 Intersegment revenues 1,141 — 126 1,267 Total segment revenues $ 1,270 $ 3,204 $ 18,354 $ 22,828 Three Months Ended September 30, 2020 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 5,381 $ 2,974 $ 15,228 $ 23,583 Intersegment revenues 1,919 — 55 1,974 Total segment revenues $ 7,300 $ 2,974 $ 15,283 $ 25,557 Nine Months Ended September 30, 2021 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 723 $ 9,860 $ 69,069 $ 79,652 Intersegment revenues 1,469 — 324 1,793 Total segment revenues $ 2,192 $ 9,860 $ 69,393 $ 81,445 Nine Months Ended September 30, 2020 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 20,703 $ 7,230 $ 55,858 $ 83,791 Intersegment revenues 5,521 — 254 5,775 Total segment revenues $ 26,224 $ 7,230 $ 56,112 $ 89,566 The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Total segment revenues from reportable segments $ 22,828 $ 25,557 $ 81,445 $ 89,566 Other revenues — — — 54 Elimination of intersegment revenues (1,267) (1,974) (1,793) (5,775) Total consolidated revenues $ 21,561 $ 23,583 $ 79,652 $ 83,845 As of September 30, 2021 and December 31, 2020, the Company had $4,869 and $5,908, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $93 and $118 for the three months ended September 30, 2021 and 2020, respectively, and $443 and $481 for the nine months ended September 30, 2021 and 2020, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and note disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2021 and results of operations and cash flows for the interim periods ended September 30, 2021 and 2020. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2021, or for any other future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in
Consolidation	The accompanying condensed consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Equity Method Investments	Equity Method InvestmentsThe Company accounts for its investments in each of its joint ventures ("JVs") and accounted for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest.
Variable Interest Entities	Variable Interest EntitiesAs of September 30, 2021 and December 31, 2020, the Company determined that its JVs were variable interest entities ("VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs.
Segment Information	Segment Information The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. Starting in the first quarter of 2021, the financial information regularly reviewed by the CODM was revised and the operating segments, which were determined to be operating and reportable segments, were (i) Biopharmaceuticals, (ii) Exemplar, and (iii) Trans Ova. The legal entities of PGEN Therapeutics and ActoBio, as well as the Company's majority-owned subsidiary Triple-Gene LLC and its partnered program with Castle Creek Biosciences, Inc. ("
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification ("ASC") Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. The Company adopted this standard effective January 1, 2021, and there was no material impact to the accompanying condensed consolidated financial statements. Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06" ) . The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021, and is effective for the Company for the year ending December 31, 2022. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale or abandonment related to MBP Titan as of September 30, 2021 and December 31, 2020, are as follows: September 30, December 31, Assets Property, plant and equipment, net $ — $ 586 Right-of-use assets — 9,131 Other assets — 136 Total assets held for sale or abandonment $ — $ 9,853 Liabilities Lease liabilities, current $ — $ 1,890 Other current liabilities — 619 Lease liabilities, net of current portion — 11,538 Total liabilities held for sale or abandonment $ — $ 14,047 The following table presents the financial results of discontinued operations related to MBP Titan: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating (gains) expenses (1) $ (60) $ 1,972 $ (4,599) $ 38,713 Operating income (loss) 60 (1,972) 4,599 (38,713) Income (loss) before income taxes 60 (1,972) 4,599 (38,713) Income (loss) from discontinued operations $ 60 $ (1,972) $ 4,599 $ (38,713) (1) Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and right-of-use assets of $12,406 in the nine months ended September 30, 2020 in conjunction with the suspension of MBP Titan's operations discussed above. The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan that are included in the accompanying condensed consolidated statements of cash flows. Nine Months Ended 2021 2020 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 2,337 Impairment of goodwill — 9,635 Impairment of other noncurrent assets — 12,406 (Gain) loss on disposals of assets, net (464) 13 Stock-based compensation expense — (34) Gain on lease termination (1) (4,602) — Cash flows from investing activities Purchases of property, plant and equipment — (88) Proceeds from sales of assets 1,083 — (1) Included in other noncash items on the accompanying condensed consolidated statement of cash flows. The following table presents the financial results of discontinued operations related to the Transactions for the nine months ended September 30, 2020. There were no discontinued operations related to the Transactions for the three months ended September 30, 2020. Nine Months Ended September 30, 2020 TS Biotechnology Sale EnviroFlight Sale Total Revenues (1) $ 1,294 $ — $ 1,294 Operating expenses 896 — 896 Operating income 398 — 398 Gain on sale of discontinued operations 633 39 672 Loss on release of cumulative foreign currency translation adjustment (26,957) — (26,957) Other expense, net (129) — (129) Equity in net loss of affiliates — (38) (38) Income (loss) before income taxes (26,055) 1 (26,054) Income tax expense (2) — (2) Income (loss) from discontinued operations $ (26,057) $ 1 $ (26,056) (1) Includes revenue recognized from related parties of $436. The following table presents the significant noncash items and purchases of property, plant and equipment for the discontinued operations related to the Transactions that are included in the accompanying condensed consolidated statement of cash flows. Nine Months Ended Adjustments to reconcile net loss to net cash used in operating activities Gain on sale of discontinued operations $ (672) Loss on release of cumulative foreign currency translation adjustment 26,957 Unrealized depreciation on equity securities 106 Equity in net loss of EnviroFlight 38 Stock-based compensation expense (1,346) Cash flows from investing activities Purchases of property, plant and equipment (382) Summarized financial data for EnviroFlight is shown in the following table for the period in which the Company held the equity method investment. Nine Months Ended Revenues $ 16 Operating expenses 92 Operating loss (76) Net loss $ (76)

Collaboration and Licensing R_2

Collaboration and Licensing Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summarized Collaboration and Licensing Revenues	The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2021 and 2020. Three Months Ended Nine Months Ended 2021 2020 2021 2020 ZIOPHARM Oncology, Inc. $ — $ — $ — $ 100 Oragenics, Inc. — 2,823 — 3,053 Castle Creek Biosciences, Inc. 18 2,394 371 16,967 Other 4 6 18 139 Total (1) $ 22 $ 5,223 $ 389 $ 20,259 (1) Collaboration and licensing revenues include the recognition of $22 and $5,213 for the three months ended September 30, 2021 and 2020, respectively, and $380 and $19,654 for the nine months ended September 30, 2021 and 2020, respectively, associated with upfront and milestone payments which were previously deferred.
Summary of Deferred Revenue	Deferred revenue consisted of the following: September 30, December 31, Collaboration and licensing agreements $ 23,040 $ 23,420 Prepaid product and service revenues 3,493 2,126 Other 183 277 Total $ 26,716 $ 25,823 Current portion of deferred revenue $ 3,693 $ 2,800 Long-term portion of deferred revenue 23,023 23,023 Total $ 26,716 $ 25,823
Summary of Deferred Revenue by Collaborator	The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2021 and December 31, 2020, as well as the estimated remaining performance period as of September 30, 2021. Average Remaining Performance Period (Years) September 30, December 31, Intrexon Energy Partners, LLC 2.5 $ 8,362 $ 8,362 Intrexon Energy Partners II, LLC 3.2 12,843 12,843 Castle Creek Biosciences, Inc. 0.3 17 379 Other 3.1 1,818 1,836 Total $ 23,040 $ 23,420

Short-term and Long-term Inve_2

Short-term and Long-term Investments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments	The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of September 30, 2021: Amortized Gross Gross Aggregate U.S. government debt securities $ 139,375 $ 5 $ (35) $ 139,345 Certificates of deposit 265 — — 265 Total $ 139,640 $ 5 $ (35) $ 139,610 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2020: Amortized Gross Gross Aggregate U.S. government debt securities $ 48,048 $ 14 $ (1) $ 48,061 Certificates of deposit 264 — — 264 Total $ 48,312 $ 14 $ (1) $ 48,325
Contractual Obligation, Fiscal Year Maturity	The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2021 was: Due within one year $ 72,684 After one year through two years 66,926 Total $ 139,610

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of September 30, 2021: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs September 30, Assets U.S. government debt securities $ — $ 139,345 $ — $ 139,345 Certificates of deposit — 265 — 265 Total $ — $ 139,610 $ — $ 139,610 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2020: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 48,061 $ — $ 48,061 Certificates of deposit — 264 — 264 Total $ — $ 48,325 $ — $ 48,325

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: September 30, December 31, Supplies, embryos and other production materials $ 2,230 $ 2,060 Work in process 1,837 2,348 Livestock 3,803 5,047 Feed 2,066 1,904 Total inventory $ 9,936 $ 11,359

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following: September 30, December 31, Land and land improvements $ 9,844 $ 9,844 Buildings and building improvements 12,088 12,088 Furniture and fixtures 1,236 1,228 Equipment 32,634 31,150 Leasehold improvements 6,452 6,260 Breeding stock 968 868 Computer hardware and software 5,425 5,684 Construction and other assets in progress 2,729 2,754 71,376 69,876 Less: Accumulated depreciation and amortization (38,619) (34,952) Property, plant and equipment, net $ 32,757 $ 34,924

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2021 were as follows: Balance at December 31, 2020 $ 54,363 Foreign currency translation adjustments (157) Balance at September 30, 2021 $ 54,206
Schedule of Intangible Assets	Intangible assets consist of the following as of September 30, 2021: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 92,859 $ (37,667) $ 55,192 Customer relationships 10,850 (10,024) 826 Trademarks 5,900 (5,004) 896 Total $ 109,609 $ (52,695) $ 56,914 Intangible assets consist of the following as of December 31, 2020: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 96,927 $ (34,412) $ 62,515 Customer relationships 10,850 (9,340) 1,510 Trademarks 5,900 (4,529) 1,371 Total $ 113,677 $ (48,281) $ 65,396

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	Long-term debt consists of the following: September 30, December 31, Convertible debt $ 176,788 $ 168,147 Notes payable 3,328 3,655 Other 56 80 Long-term debt 180,172 171,882 Less current portion 355 360 Long-term debt, less current portion $ 179,817 $ 171,522
Schedule of Components of Interest Expense	The components of interest expense related to the Convertible Notes were as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cash interest expense $ 1,750 $ 1,750 $ 5,250 $ 5,250 Non-cash interest expense 3,011 2,706 8,641 7,807 Total interest expense $ 4,761 $ 4,456 $ 13,891 $ 13,057
Schedule of Future Maturities of Long-Term Debt	Future maturities of long-term debt as of September 30, 2021 are as follows: 2021 $ 90 2022 400 2023 200,363 2024 378 2025 393 2026 408 Thereafter 1,352 Total $ 203,384

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The following table presents the components of income tax benefit from continuing operations. Three Months Ended Nine Months Ended 2021 2020 2021 2020 Current foreign income tax expense from continuing operations $ — $ 18 $ 7 $ 74 Deferred income tax benefit from continuing operations (61) (68) (180) (204) Total income tax benefit from continuing operations $ (61) $ (50) $ (173) $ (130)

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	The components of accumulated other comprehensive income are as follows: September 30, December 31, Unrealized gain (loss) on investments $ (30) $ 13 Income on foreign currency translation adjustments 1,545 3,984 Total accumulated other comprehensive income $ 1,515 $ 3,997

Share-Based Payments (Tables)

Share-Based Payments (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Costs	Stock-based compensation costs included in the condensed consolidated statements of operations are presented below: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of products $ 8 $ 1 $ 23 $ 7 Cost of services 35 35 134 99 Research and development 555 435 2,180 1,383 Selling, general and administrative 1,892 4,157 9,125 13,760 Discontinued operations — (28) — (1,380) Total $ 2,490 $ 4,600 $ 11,462 $ 13,869
Schedule of Stock Option Activity	Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2020 11,255,896 $ 15.53 7.25 Granted 1,802,820 8.02 Exercised (126,508) (4.77) Forfeited (255,467) (6.83) Expired (427,632) (25.93) Balances at September 30, 2021 12,249,109 14.35 6.89 Exercisable at September 30, 2021 7,227,624 16.87 5.68
Schedule of Restricted Stock Unit Activity	RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2020 1,727,712 $ 6.11 0.42 Granted 462,019 7.87 Vested (1,624,013) (5.76) Forfeited (97,237) (8.96) Balances at September 30, 2021 468,481 8.47 0.58

Operating Leases (Tables)

Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Components of Lease Costs	The components of lease costs were as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating lease costs $ 843 $ 892 $ 2,511 $ 2,690 Short-term lease costs 464 480 1,411 1,332 Variable lease costs 199 205 663 654 Lease costs $ 1,506 $ 1,577 $ 4,585 $ 4,676 Other information related to operating leases in continuing operations was as follows: September 30, December 31, Weighted average remaining lease term (years) 6.38 4.21 Weighted average discount rate 10.99 % 10.27 % Nine Months Ended 2021 2020 Supplemental disclosure of cash flow information Cash paid for operating lease liabilities $ 2,835 $ 3,013 Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases) 4,868 395
Maturities of Lease Liabilities	As of September 30, 2021, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2021 $ 718 2022 3,405 2023 2,945 2024 3,009 2025 2,283 2026 1,796 Thereafter 4,638 Total 18,794 Present value adjustment (5,636) Total $ 13,158 Current portion of operating lease liabilities $ 1,959 Long-term portion of operating lease liabilities 11,199 Total $ 13,158

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss per Share	The following table presents the computation of basic and diluted net income (loss) per share: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Historical net loss per share: Numerator: Net loss from continuing operations $ (29,824) $ (27,536) $ (71,731) $ (64,091) Net income (loss) from discontinued operations 60 (1,972) 4,599 (64,769) Net loss $ (29,764) $ (29,508) $ (67,132) $ (128,860) Denominator: Weighted average shares outstanding, basic and diluted 199,179,963 165,527,024 197,254,438 163,318,375 Net loss per share: Net loss from continuing operations per share, basic and diluted $ (0.15) $ (0.17) $ (0.36) $ (0.39) Net income (loss) from discontinued operations per share, basic and diluted — (0.01) 0.02 (0.40) Net loss per share, basic and diluted $ (0.15) $ (0.18) $ (0.34) $ (0.79)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share	The following potentially dilutive securities as of September 30, 2021 and 2020, have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended as they would have been anti-dilutive: September 30, 2021 2020 Convertible debt 11,732,440 17,843,715 Options 12,249,109 11,379,605 Restricted stock units 468,481 1,813,043 Warrants 121,888 133,264 Total 24,571,918 31,169,627

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Information by Reportable Segment	Segment Adjusted EBITDA by reportable segment was as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Biopharmaceuticals $ (12,661) $ (8,761) $ (34,055) $ (26,106) Exemplar 1,617 1,654 5,312 2,511 Trans Ova (2,552) (251) 15,881 7,417 Segment Adjusted EBITDA for reportable segments $ (13,596) $ (7,358) $ (12,862) $ (16,178) Revenues by reportable segment were as follows: Three Months Ended September 30, 2021 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 129 $ 3,204 $ 18,228 $ 21,561 Intersegment revenues 1,141 — 126 1,267 Total segment revenues $ 1,270 $ 3,204 $ 18,354 $ 22,828 Three Months Ended September 30, 2020 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 5,381 $ 2,974 $ 15,228 $ 23,583 Intersegment revenues 1,919 — 55 1,974 Total segment revenues $ 7,300 $ 2,974 $ 15,283 $ 25,557 Nine Months Ended September 30, 2021 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 723 $ 9,860 $ 69,069 $ 79,652 Intersegment revenues 1,469 — 324 1,793 Total segment revenues $ 2,192 $ 9,860 $ 69,393 $ 81,445 Nine Months Ended September 30, 2020 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 20,703 $ 7,230 $ 55,858 $ 83,791 Intersegment revenues 5,521 — 254 5,775 Total segment revenues $ 26,224 $ 7,230 $ 56,112 $ 89,566
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Segment Adjusted EBITDA for reportable segments $ (13,596) $ (7,358) $ (12,862) $ (16,178) Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates 1,962 244 3,360 3,395 Add recognition of previously deferred revenue associated with upfront and milestone payments 1,163 7,132 1,849 25,178 Other expenses: Interest expense (4,799) (4,646) (14,005) (13,830) Depreciation and amortization (3,399) (3,786) (10,442) (11,364) Loss on disposals of assets (318) (615) (553) (1,593) Impairment losses — (920) (543) (920) Stock-based compensation expense (2,490) (4,628) (11,462) (15,249) Adjustment related to accrued bonuses paid in equity awards — — — 2,833 Equity in net loss of affiliates — (523) (3) (1,125) Other (5) 4 (19) 16 Unallocated corporate costs (7,166) (10,452) (25,412) (29,102) Eliminations (1,237) (2,038) (1,812) (6,282) Consolidated net loss from continuing operations before income taxes $ (29,885) $ (27,586) $ (71,904) $ (64,221)
Reconciliation of Revenue from Segments to Consolidated	The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Total segment revenues from reportable segments $ 22,828 $ 25,557 $ 81,445 $ 89,566 Other revenues — — — 54 Elimination of intersegment revenues (1,267) (1,974) (1,793) (5,775) Total consolidated revenues $ 21,561 $ 23,583 $ 79,652 $ 83,845

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Liquidity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Net loss	$ (29,764)	$ (29,508)	$ (67,132)	$ (128,860)
Accumulated deficit	$ 1,890,522		$ 1,890,522		$ 1,823,390

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Maximum risk of loss related to the identified VIEs	$ 0	$ 0

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jan. 02, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of assets				$ (89,000)	$ (1,606,000)
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations				0	26,957,000
Net income (loss) from discontinued operations		$ 60,000	$ (1,972,000)	4,599,000	(64,769,000)
MBP Titan | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of assets				464,000	(13,000)
Gain on lease termination				4,602,000	0
Net income (loss) from discontinued operations		$ 60,000	(1,972,000)	$ 4,599,000	(38,713,000)
TS Biotechnology Holdings LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration	$ 53,000,000
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	$ 26,957,000				26,957,000
Net income (loss) from discontinued operations					(26,057,000)
Prior period adjustment, loss					26,572,000
EnviroFlight, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration						$ 12,200,000
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations					0
Net income (loss) from discontinued operations					1,000
TS Biotechnology Holdings LLC and EnviroFlight LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations					26,957,000
Net income (loss) from discontinued operations			$ 0		$ (26,056,000)

Discontinued Operations - Carry

Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - MBP Titan - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Property, plant and equipment, net	$ 0	$ 586
Right-of-use assets	0	9,131
Other assets	0	136
Total assets held for sale or abandonment	0	9,853
Liabilities
Lease liabilities, current	0	1,890
Other current liabilities	0	619
Lease liabilities, net of current portion	0	11,538
Total liabilities held for sale or abandonment	$ 0	$ 14,047

Discontinued Operations - Summa

Discontinued Operations - Summary of Financial Results for MBP Titan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations	$ 60	$ (1,972)	$ 4,599	$ (64,769)
Impairment of goodwill			0	9,635
MBP Titan | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Operating (gains) expenses	(60)	1,972	(4,599)	38,713
Operating income (loss)	60	(1,972)	4,599	(38,713)
Income (loss) before income taxes	60	(1,972)	4,599	(38,713)
Income (loss) from discontinued operations	$ 60	$ (1,972)	4,599	(38,713)
Impairment of goodwill			$ 0	9,635
Impairment of other noncurrent assets				$ 12,406

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$ 10,442	$ 13,701
Impairment of goodwill	0	9,635
Impairment of other noncurrent assets	543	13,326
(Gain) loss on disposals of assets, net	89	1,606
Stock-based compensation expense	11,462	13,869
Cash flows from investing activities
Purchases of property, plant and equipment	(4,474)	(6,058)
Proceeds from sale of assets	2,537	1,831
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment | MBP Titan
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	0	2,337
Impairment of goodwill	0	9,635
Impairment of other noncurrent assets	0	12,406
(Gain) loss on disposals of assets, net	(464)	13
Stock-based compensation expense	0	(34)
Gain on lease termination	(4,602)	0
Cash flows from investing activities
Purchases of property, plant and equipment	0	(88)
Proceeds from sale of assets	$ 1,083	$ 0

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustment				$ 0	$ (26,957,000)
Income (loss) from discontinued operations		$ 60,000	$ (1,972,000)	$ 4,599,000	(64,769,000)
TS Biotechnology Holdings LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue					1,294,000
Operating expenses					896,000
Operating income (loss)					398,000
Gain on sale of discontinued operations					633,000
Loss on release of cumulative foreign currency translation adjustment	$ (26,957,000)				(26,957,000)
Other expense, net					(129,000)
Income (loss) before income taxes					(26,055,000)
Income tax expense					(2,000)
Income (loss) from discontinued operations					(26,057,000)
EnviroFlight, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue					0
Operating expenses					0
Operating income (loss)					0
Gain on sale of discontinued operations					39,000
Loss on release of cumulative foreign currency translation adjustment					0
Other expense, net					0
Equity in net loss of affiliates					(38,000)
Income (loss) before income taxes					1,000
Income tax expense					0
Income (loss) from discontinued operations					1,000
TS Biotechnology Holdings LLC and EnviroFlight LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue					1,294,000
Operating expenses					896,000
Operating income (loss)					398,000
Gain on sale of discontinued operations					672,000
Loss on release of cumulative foreign currency translation adjustment					(26,957,000)
Other expense, net					(129,000)
Equity in net loss of affiliates					(38,000)
Income (loss) before income taxes					(26,054,000)
Income tax expense					(2,000)
Income (loss) from discontinued operations			$ 0		(26,056,000)
Related Parties, Aggregated | TS Biotechnology Holdings LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue					$ 436,000

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sale of discontinued operations	$ 0	$ (672)
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	0	26,957
Equity in net loss of EnviroFlight	3	1,163
Stock-based compensation expense	11,462	13,869
Purchases of property, plant and equipment	$ (4,474)	(6,058)
TS Biotechnology Holdings LLC and EnviroFlight LLC | Discontinued Operations, Disposed of by Sale
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sale of discontinued operations		(672)
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations		26,957
Unrealized depreciation on equity securities		106
Stock-based compensation expense		(1,346)
Purchases of property, plant and equipment		(382)
EnviroFlight, LLC | Discontinued Operations, Disposed of by Sale
Adjustments to reconcile net loss to net cash used in operating activities
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations		0
Equity in net loss of EnviroFlight		$ 38

Discontinued Operations - Sum_4

Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees - EnviroFlight, LLC - Discontinued Operations, Disposed of by Sale $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	$ 16
Operating expenses	92
Operating loss	(76)
Net loss	$ (76)

Investments in Joint Ventures -

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2014USD ($)	Sep. 30, 2021USD ($)board_seat	Dec. 31, 2020USD ($)
Intrexon Energy Partners, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Maximum additional capital contribution committed	$ 25,000,000
Additional capital contributions committed, remaining commitment		$ 4,225,000
Total number of seats on the joint venture's governing board | board_seat		5
Total number of seats on the joint venture's governing board, internally selected | board_seat		2
Total number of seats on the joint venture's governing board, externally selected | board_seat		3
Intrexon Energy Partners, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (428,000)	$ (425,000)
Intrexon Energy Partners, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Capital contributions	$ 25,000,000
Maximum additional capital contribution committed	25,000,000
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 25,000,000

Investments in Joint Ventures_2

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015USD ($)board_seat	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Intrexon Energy Partners II, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Maximum additional capital contribution committed	$ 10,000,000
Additional capital contributions committed, remaining commitment		$ 10,000,000
Total number of seats on the joint venture's governing board | board_seat	5
Total number of seats on the joint venture's governing board, internally selected | board_seat	1
Total number of seats on the joint venture's governing board, externally selected | board_seat	4
Intrexon Energy Partners II, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (435,000)	$ (435,000)
Intrexon Energy Partners II, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Capital contributions	$ 18,000,000
Maximum additional capital contribution committed	10,000,000
Intrexon Energy Partners II, LLC | All Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	4,000,000
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 18,000,000

Collaboration and Licensing R_3

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 21,561	$ 23,583	$ 79,652	$ 83,845
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	22	5,223	389	20,259
Upfront and milestone payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	22	5,213	380	19,654
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	0	0	0	100
Oragenics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	0	2,823	0	3,053
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	18	2,394	371	16,967
Other | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 4	$ 6	$ 18	$ 139

Collaboration and Licensing R_4

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 26,716	$ 25,823
Current portion of deferred revenue	3,693	2,800
Long-term portion of deferred revenue	23,023	23,023
Collaboration and licensing agreements
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	23,040	23,420
Prepaid product and service revenues
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	3,493	2,126
Other
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 183	$ 277

Collaboration and Licensing R_5

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 23,420
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 23,040
Intrexon Energy Partners, LLC | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		8,362
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	2 years 6 months
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 8,362
Intrexon Energy Partners II, LLC | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		12,843
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	3 years 2 months 12 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 12,843
Castle Creek Biosciences, Inc. | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		379
Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	3 months 18 days
Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 17
Other | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 1,836
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Contract With Customer, Asset And Liability [Line Items]
Average Remaining Performance Period (Years)	3 years 1 month 6 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 1,818

Short-term and Long-term Inve_3

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 139,640	$ 48,312
Gross Unrealized Gains	5	14
Gross Unrealized Losses	(35)	(1)
Aggregate Fair Value	139,610	48,325
U.S. government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	139,375	48,048
Gross Unrealized Gains	5	14
Gross Unrealized Losses	(35)	(1)
Aggregate Fair Value	139,345	48,061
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	265	264
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 265	$ 264

Short-term and Long-term Inve_4

Short-term and Long-term Investments - Contractual Obligation, Fiscal Year Maturity (Details) $ in Thousands	Sep. 30, 2021USD ($)
Investments, Debt and Equity Securities [Abstract]
Due within one year	$ 72,684
After one year through two years	66,926
Total	$ 139,610

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 139,610	$ 48,325
Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	139,610	48,325
Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	139,345	48,061
U.S. government debt securities | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	139,345	48,061
U.S. government debt securities | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Certificates of deposit
Assets
Fair value of financial assets measured at fair value on a recurring basis	265	264
Certificates of deposit | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Certificates of deposit | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	265	264
Certificates of deposit | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Jul. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, interest rate, stated percentage	3.50%		3.50%
Fair value of convertible debt	$ 169,000	$ 165,000
Carrying value of convertible debt	$ 176,788	$ 168,147	$ 143,723

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory [Line Items]
Inventory	$ 9,936	$ 11,359
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	2,230	2,060
Work in process
Inventory [Line Items]
Inventory	1,837	2,348
Livestock
Inventory [Line Items]
Inventory	3,803	5,047
Feed
Inventory [Line Items]
Inventory	$ 2,066	$ 1,904

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 9,844	$ 9,844
Buildings and building improvements	12,088	12,088
Furniture and fixtures	1,236	1,228
Equipment	32,634	31,150
Leasehold improvements	6,452	6,260
Breeding stock	968	868
Computer hardware and software	5,425	5,684
Construction and other assets in progress	2,729	2,754
Property, plant and equipment, gross	71,376	69,876
Less: Accumulated depreciation and amortization	(38,619)	(34,952)
Property, plant and equipment, net	$ 32,757	$ 34,924

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,525	$ 1,873	$ 4,711	$ 5,689

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill
Beginning balance	$ 54,363
Foreign currency translation adjustments	(157)
Ending balance	$ 54,206

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill accumulated impairment losses	$ 43,643		$ 43,643		$ 43,643
Amortization expense	$ 1,874	$ 1,913	$ 5,731	$ 5,675

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	$ 109,609	$ 113,677
Accumulated Amortization	(52,695)	(48,281)
Net	56,914	65,396
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	92,859	96,927
Accumulated Amortization	(37,667)	(34,412)
Net	55,192	62,515
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	10,850	10,850
Accumulated Amortization	(10,024)	(9,340)
Net	826	1,510
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	5,900	5,900
Accumulated Amortization	(5,004)	(4,529)
Net	$ 896	$ 1,371

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of credit facility, interest rate at period end	3.25%
Line of credit facility, outstanding balance	$ 0	$ 0
Line of credit facility, current borrowing capacity	$ 5,000,000
Trans Ova Genetics, LC | First National Bank of Omaha | Minimum
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%
Exemplar Genetics, LLC | American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	4.00%
Line of credit facility, outstanding balance	$ 0	$ 0

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Schedule of Long-Term Debt Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long-term debt	$ 180,172	$ 171,882
Less current portion	355	360
Long-term debt, less current portion	179,817	171,522
Convertible debt
Debt Instrument [Line Items]
Long-term debt	176,788	168,147
Notes payable
Debt Instrument [Line Items]
Long-term debt	3,328	3,655
Other
Debt Instrument [Line Items]
Long-term debt	$ 56	$ 80

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended			3 Months Ended	9 Months Ended
	Oct. 31, 2020shares	Sep. 30, 2020shares	Jul. 31, 2018USD ($)day$ / shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)
Debt Instrument [Line Items]
Deferred income taxes					$ (180,000)	$ (204,000)
Accrued interest					1,750,000
Long-term debt					180,172,000		$ 171,882,000
Convertible debt
Debt Instrument [Line Items]
Long-term debt					176,788,000		168,147,000
Notes payable
Debt Instrument [Line Items]
Long-term debt					$ 3,328,000		3,655,000
Precigen ActoBio Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage									3.00%
Interest expense				$ 147,000		$ 616,000
Trans Ova Genetics, LC | Notes payable | American State Bank
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					3.95%
Long-term debt					$ 3,328,000
Debt instrument, periodic payment					39,000
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio Inc.
Debt Instrument [Line Items]
Aggregate principal amount									$ 30,000,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount			$ 200,000,000		$ 200,000,000
Proceeds from long-term debt, net of issuance costs			193,958,000
Debt issuance costs			$ 6,042,000
Debt instrument, interest rate, stated percentage			3.50%		3.50%
Conversion rate			58.6622
Principal amount used in conversion			$ 1,000
Conversion price (in usd per share) | $ / shares			$ 17.05
Debt instrument redemption price, percentage			100.00%
Carrying value of convertible debt			$ 143,723,000		$ 176,788,000		$ 168,147,000
Equity component of convertible debt, net of issuance costs and deferred taxes			50,235,000
Deferred income taxes			$ 13,367,000
Effective interest rate on convertible notes					11.02%
Convertible notes, unamortized discount and issuance costs					$ 23,212,000
3.5% Convertible Notes Due 2023 | Minimum
Debt Instrument [Line Items]
Common stock price trading days | day			20
Common stock price consecutive trading days | day			30
Percentage of common share price over conversion price for conversion			130.00%
3.5% Convertible Notes Due 2023 | Maximum
Debt Instrument [Line Items]
Common stock price trading days | day			5
Common stock price consecutive trading days | day			5
Debt instrument redemption price, percentage			98.00%
ActoBio Notes
Debt Instrument [Line Items]
Debt conversion, converted instrument, shares issued (in shares) | shares		6,293,402
Merck Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount								$ 25,000,000
Debt conversion, converted instrument, shares issued (in shares) | shares	6,758,400

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Schedule of Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Cash interest expense	$ 1,750	$ 1,750	$ 5,250	$ 5,250
Non-cash interest expense	3,011	2,706	8,641	7,807
Total interest expense	$ 4,761	$ 4,456	$ 13,891	$ 13,057

Lines of Credit and Long-Term_7

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Sep. 30, 2021USD ($)
Debt Disclosure [Abstract]
2021	$ 90
2022	400
2023	200,363
2024	378
2025	393
2026	408
Thereafter	1,352
Total	$ 203,384

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Loss Carryforwards [Line Items]
Deferred tax liabilities	$ 2,574		$ 2,574
Domestic
Operating Loss Carryforwards [Line Items]
Taxable loss	(24,700)	$ (26,900)	(82,200)	$ (133,900)
Operating loss carryforwards	836,600		836,600
Deferred tax assets, capital loss carryforwards	212,500		212,500
Research and development tax credits	10,900		10,900
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	76,800		76,800
Generated After 2017
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 583,900		$ 583,900

Income Taxes - Components of In

Income Taxes - Components of Income Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit from continuing operations			$ (180)	$ (204)
Continuing Operations
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit from continuing operations	$ (61)	$ (68)	(180)	(204)
Total income tax benefit from continuing operations	(61)	(50)	(173)	(130)
Continuing Operations | Foreign
Operating Loss Carryforwards [Line Items]
Current income tax expense from continuing operations	$ 0	$ 18	$ 7	$ 74

Shareholders' Equity - Issuance

Shareholders' Equity - Issuances of Precigen Common Stock (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Class of Stock [Line Items]
Shares issued (in shares)		17,250,000
Shares issued during the period, value		$ 121,045	$ 121,045	$ 35,000
Adjustments to additional paid in capital, stock issued, issuance costs		$ 568
TS Biotechnology Holdings LLC
Class of Stock [Line Items]
Shares issued (in shares)	5,972,696
Shares issued during the period, value	$ 35,000

Shareholders' Equity - Share Le

Shareholders' Equity - Share Lending Agreement (Details)	1 Months Ended
	Jul. 31, 2018$ / sharesshares
Equity [Abstract]
Borrowed shares, number issued (in shares) | shares	7,479,431
Share lending agreement, length of time for shares to be returned upon termination	5 days
Borrowed shares, public offering price per share (in usd per share) | $ / shares	$ 13.37

Shareholders' Equity - Componen

Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ 131,247	$ 159,196	$ 67,174	$ 58,552	$ 49,542	$ 71,711
Total accumulated other comprehensive income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	1,515	$ 2,541	3,997	$ 1,362	$ (650)	$ (27,468)
Unrealized gain (loss) on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	(30)		13
Income on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ 1,545		$ 3,984

Share-Based Payments - Schedule

Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ 2,490	$ 4,600	$ 11,462	$ 13,869
Cost of products
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	8	1	23	7
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	35	35	134	99
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	555	435	2,180	1,383
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	1,892	4,157	9,125	13,760
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ 0	$ (28)	$ 0	$ (1,380)

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly compensation, in the form of equity				$ 200
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lock-up period				3 years
Yearly compensation, payable in cash or equity	$ 100
Share-based Payment Arrangement, Option | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual stock option grant, grant date fair value	250
Restricted stock units | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual RSU grant, grant date fair value	$ 250
Share-based compensation arrangement by share-based payment award, award vesting period	1 year
Selling, general and administrative | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense for certain compensation arrangements		$ 76	$ 266		$ 585	$ 720
Precigen Stock Option Plan 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)		0			0
Options outstanding (in shares)		104,354			104,354
Precigen Stock Option Plan 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)		5,900,357			5,900,357
Options outstanding (in shares)		11,078,437			11,078,437
Number of shares authorized for issuance (in shares)		27,000,000			27,000,000
RSUs outstanding (in shares)		306,360			306,360
Precigen Stock Option Plan 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)		1,974,662			1,974,662
Options outstanding (in shares)		1,066,318			1,066,318
Number of shares authorized for issuance (in shares)		5,000,000			5,000,000
RSUs outstanding (in shares)		162,121			162,121

Share-Based Payments - Schedu_2

Share-Based Payments - Schedule of Stock Option Activity (Details) - Precigen Stock Option Plans - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Number of Shares
Balances at beginning of period (in shares)	11,255,896
Granted (in shares)	1,802,820
Exercised (in shares)	(126,508)
Forfeited (in shares)	(255,467)
Expired (in shares)	(427,632)
Balances at end of period (in shares)	12,249,109	11,255,896
Exercisable at end of period (in shares)	7,227,624
Weighted Average Exercise Price
Balances at beginning of period (in usd per share)	$ 15.53
Granted (in usd per share)	8.02
Exercised (in usd per share)	(4.77)
Forfeited (in usd per share)	(6.83)
Expired (in usd per share)	(25.93)
Balances at period end (in usd per share)	14.35	$ 15.53
Exercisable, weighted average exercise price, at end of period (in usd per share)	$ 16.87
Weighted Average Remaining Contractual Term (Years)
Balances, weighted average remaining contractual period	6 years 10 months 20 days	7 years 3 months
Exercisable at period end, weighted average remaining contractual period	5 years 8 months 4 days

Share-Based Payments - Schedu_3

Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - Precigen Stock Option Plans - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Number of Restricted Stock Units
Balances at beginning of period (in shares)	1,727,712
Granted (in shares)	462,019
Vested (in shares)	(1,624,013)
Forfeited (in shares)	(97,237)
Balances at end of period (in shares)	468,481	1,727,712
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 6.11
Granted (in usd per share)	7.87
Vested (in usd per share)	(5.76)
Forfeited (in usd per share)	(8.96)
Balances at end of period (in usd per share)	$ 8.47	$ 6.11
Additional Information
Weighted Average Remaining Contractual Term (Years)	6 months 29 days	5 months 1 day

Operating Leases - Additional I

Operating Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	9 years

Operating Leases - Components o

Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Operating lease costs	$ 843	$ 892	$ 2,511	$ 2,690
Short-term lease costs	464	480	1,411	1,332
Variable lease costs	199	205	663	654
Lease costs	$ 1,506	$ 1,577	$ 4,585	$ 4,676

Operating Leases - Maturities o

Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	$ 718
2022	3,405
2023	2,945
2024	3,009
2025	2,283
2026	1,796
Thereafter	4,638
Total	18,794
Present value adjustment	(5,636)
Total	13,158
Current portion of lease liabilities	1,959	$ 2,657
Long-term portion of operating lease liabilities	$ 11,199	$ 7,744

Operating Leases - Lease Terms

Operating Leases - Lease Terms and Discount Rates (Details)	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted average remaining lease term (years)	6 years 4 months 17 days	4 years 2 months 15 days
Weighted average discount rate	10.99%	10.27%

Operating Leases - Other Inform

Operating Leases - Other Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Supplemental disclosure of cash flow information
Cash paid for operating lease liabilities	$ 2,835	$ 3,013
Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases)	$ 4,868	$ 395

Commitments and Contingencies -

Commitments and Contingencies - Contingencies - Additional Information (Details) $ in Thousands	Dec. 01, 2020claim	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)patent	Nov. 30, 2020USD ($)claim
Loss Contingencies [Line Items]
Deferred revenue		$ 25,823		$ 26,716
Collaboration and licensing agreements
Loss Contingencies [Line Items]
Deferred revenue		$ 23,420		$ 23,040
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc.
Loss Contingencies [Line Items]
Investment					$ 326
XY, LLC | Licensing and patent infringement suit
Loss Contingencies [Line Items]
Loss contingency, claims settled, number | claim	1
Claims pending resolution | claim					2
Loss contingency, number of patents | patent				5
Division Of Enforcement Of The Securities And Exchange Commission | Methane Bioconversion Platform Disclosures
Loss Contingencies [Line Items]
Payments for civil money penalty			$ 2,500
Harvest Intrexon Enterprise Fund I, LP
Loss Contingencies [Line Items]
Stock issued in conjunction with settlement agreement, shares | shares		2,117,264
Shares issued in conjunction with settlement agreement		$ 18,103
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements
Loss Contingencies [Line Items]
Deferred revenue					$ 6,993

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Third Security, LLC
Related Party Transaction [Line Items]
Expense for services			$ 43	$ 56	$ 89	$ 132
Sublease rental income			$ 20	$ 18	$ 61	$ 64
Castle Creek Biosciences, Inc.
Related Party Transaction [Line Items]
Proceeds from sale and maturity of other investments		$ 1,280
Proceeds from convertible notes receivable and investment in preferred stock	$ 3,311
Third Security, LLC | Executive Chairman
Related Party Transaction [Line Items]
Ownership interest			100.00%		100.00%

Net Loss per Share - Computatio

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss from continuing operations	$ (29,824)	$ (27,536)	$ (71,731)	$ (64,091)
Net income (loss) from discontinued operations	60	(1,972)	4,599	(64,769)
Net loss	$ (29,764)	$ (29,508)	$ (67,132)	$ (128,860)
Denominator:
Weighted average shares outstanding, basic (in shares)	199,179,963	165,527,024	197,254,438	163,318,375
Weighted average shares outstanding, diluted (in shares)	199,179,963	165,527,024	197,254,438	163,318,375
Net Loss Per Share [Abstract]
Net loss from continuing operations per share, basic (in dollars per share)	$ (0.15)	$ (0.17)	$ (0.36)	$ (0.39)
Net loss from continuing operating per share, diluted (in dollars per share)	(0.15)	(0.17)	(0.36)	(0.39)
Net income (loss) from discontinued operations per share, basic (in dollars per share)	0	(0.01)	0.02	(0.40)
Net income (loss) from discontinued operations per share, diluted (in dollars per share)	0	(0.01)	0.02	(0.40)
Net loss per share, basic (in dollars per share)	(0.15)	(0.18)	(0.34)	(0.79)
Net loss per share, diluted (in dollars per share)	$ (0.15)	$ (0.18)	$ (0.34)	$ (0.79)

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	24,571,918	31,169,627	24,571,918	31,169,627
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	11,732,440	17,843,715	11,732,440	17,843,715
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	12,249,109	11,379,605	12,249,109	11,379,605
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	468,481	1,813,043	468,481	1,813,043
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	121,888	133,264	121,888	133,264

Segments - Adjusted EBITDA by R

Segments - Adjusted EBITDA by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (13,596)	$ (7,358)	$ (12,862)	$ (16,178)
Biopharmaceuticals
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	(12,661)	(8,761)	(34,055)	(26,106)
Exemplar
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	1,617	1,654	5,312	2,511
Trans Ova
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (2,552)	$ (251)	$ 15,881	$ 7,417

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (13,596)	$ (7,358)	$ (12,862)	$ (16,178)
Other expenses:
Depreciation and amortization			(10,442)	(13,701)
Loss on disposals of assets			(89)	(1,606)
Stock-based compensation expense	(2,490)	(4,600)	(11,462)	(13,869)
Equity in net loss of affiliates			(3)	(1,163)
Other			4,600	(108)
Loss before income taxes	(29,885)	(27,586)	(71,904)	(64,221)
Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	22	5,213	380	19,654
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,962	244	3,360	3,395
Operating segments | Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	1,163	7,132	1,849	25,178
Corporate And Reconciling Items
Other expenses:
Interest expense	(4,799)	(4,646)	(14,005)	(13,830)
Depreciation and amortization	(3,399)	(3,786)	(10,442)	(11,364)
Loss on disposals of assets	(318)	(615)	(553)	(1,593)
Impairment losses	0	(920)	(543)	(920)
Stock-based compensation expense	(2,490)	(4,628)	(11,462)	(15,249)
Adjustment related to accrued bonuses paid in equity awards	0	0	0	2,833
Equity in net loss of affiliates	0	(523)	(3)	(1,125)
Other	(5)	4	(19)	16
Unallocated corporate costs
Other expenses:
Loss before income taxes	(7,166)	(10,452)	(25,412)	(29,102)
Eliminations
Other expenses:
Loss before income taxes	(1,237)	(2,038)	(1,812)	(6,282)
Segment Adjusted EBITDA for reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (13,596)	$ (7,358)	$ (12,862)	$ (16,178)

Segments - Revenues by Reportab

Segments - Revenues by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Revenues from external customers	$ 21,561	$ 23,583	$ 79,652	$ 83,845
Total segment revenues from reportable segments
Segment Reporting Information [Line Items]
Revenues	22,828	25,557	81,445	89,566
Operating segments
Segment Reporting Information [Line Items]
Revenues from external customers	21,561	23,583	79,652	83,791
Revenues	22,828	25,557	81,445	89,566
Operating segments | Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues from external customers	129	5,381	723	20,703
Revenues	1,270	7,300	2,192	26,224
Operating segments | Exemplar
Segment Reporting Information [Line Items]
Revenues from external customers	3,204	2,974	9,860	7,230
Revenues	3,204	2,974	9,860	7,230
Operating segments | Trans Ova
Segment Reporting Information [Line Items]
Revenues from external customers	18,228	15,228	69,069	55,858
Revenues	18,354	15,283	69,393	56,112
Intersegment revenues
Segment Reporting Information [Line Items]
Revenues	1,267	1,974	1,793	5,775
Intersegment revenues | Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues	1,141	1,919	1,469	5,521
Intersegment revenues | Exemplar
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Intersegment revenues | Trans Ova
Segment Reporting Information [Line Items]
Revenues	126	55	324	254
Other revenues
Segment Reporting Information [Line Items]
Revenues	0	0	0	54
Elimination of intersegment revenues
Segment Reporting Information [Line Items]
Revenues	$ (1,267)	$ (1,974)	$ (1,793)	$ (5,775)

Segments - Additional Informati

Segments - Additional Information (Details) - Non-US - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Long-lived assets	$ 4,869		$ 4,869		$ 5,908
Revenues	$ 93	$ 118	$ 443	$ 481

Uncategorized Items - pgen-2021

Label	Element	Value
Restricted Cash and Cash Equivalents, Noncurrent	us-gaap_RestrictedCashAndCashEquivalentsNoncurrent	$ 458,000